Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy

A report from the children's oncology group

Xuexia Wang, Wei Liu, Can Lan Sun, Saro H. Armenian, Hakon Hakonarson, Lindsey Hageman, Yan Ding, Wendy Landier, Javier G. Blanco, Lu Chen, Adolfo Quinõnes, Daniel Ferguson, Naomi Winick, Jill P. Ginsberg, Frank Keller, Joseph P. Neglia, Sunil Desai, Charles A. Sklar, Sharon M. Castellino, Irene Cherrick & 6 others ZoAnn E. Dreyer, Melissa M. Hudson, Leslie L. Robison, Yutaka Yasui, Mary V. Relling, Smita Bhatia

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Purpose: The strong dose-dependent association between anthracyclines and cardiomyopathy is further exacerbated by the co-occurrence of cardiovascular risk factors (diabetes and hypertension). The high morbidity associated with cardiomyopathy necessitates an understanding of the underlying pathogenesis so that targeted interventions can be developed. Patients and Methods: By using a two-stage design, we investigated host susceptibility to anthracycline-related cardiomyopathy by using the ITMAT/Broad CARe cardiovascular single nucleotide polymorphism (SNP) array to profile common SNPs in 2,100 genes considered relevant to de novo cardiovascular disease. Results: By using a matched case-control design (93 cases, 194 controls), we identified a common SNP, rs2232228, in the hyaluronan synthase 3 (HAS3) gene that exerts a modifying effect on anthracycline dose-dependent cardiomyopathy risk (P = 5.3 × 10-7). Among individuals with rs2232228 GG genotype, cardiomyopathy was infrequent and not dose related. However, in individuals exposed to high-dose (> 250 mg/m2) anthracyclines, the rs2232228 AA genotype conferred an 8.9-fold (95% CI, 2.1- to 37.5-fold; P = .003) increased cardiomyopathy risk compared with the GG genotype. This gene-environment interaction was successfully replicated in an independent set of 76 patients with anthracycline-related cardiomyopathy. Relative HAS3 mRNA levels measured in healthy hearts tended to be lower among individuals with AA compared with GA genotypes (P = .09). Conclusion: Hyaluronan (HA) produced by HAS3 is a ubiquitous component of the extracellular matrix and plays an active role in tissue remodeling. In addition, HA is known to reduce reactive oxygen species (ROS)-induced cardiac injury. The high cardiomyopathy risk associated with AA genotype could be due to inadequate remodeling and/or inadequate protection of the heart from ROS-mediated injury on high anthracycline exposure.

Original languageEnglish (US)
Pages (from-to)647-653
Number of pages7
JournalJournal of Clinical Oncology
Volume32
Issue number7
DOIs
StatePublished - Mar 1 2014

Fingerprint

Anthracyclines
Cardiomyopathies
Genotype
Single Nucleotide Polymorphism
Hyaluronic Acid
Reactive Oxygen Species
Gene-Environment Interaction
hyaluronan synthase
Wounds and Injuries
Genes
Extracellular Matrix
Cardiovascular Diseases
Hypertension
Morbidity
Messenger RNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy : A report from the children's oncology group. / Wang, Xuexia; Liu, Wei; Sun, Can Lan; Armenian, Saro H.; Hakonarson, Hakon; Hageman, Lindsey; Ding, Yan; Landier, Wendy; Blanco, Javier G.; Chen, Lu; Quinõnes, Adolfo; Ferguson, Daniel; Winick, Naomi; Ginsberg, Jill P.; Keller, Frank; Neglia, Joseph P.; Desai, Sunil; Sklar, Charles A.; Castellino, Sharon M.; Cherrick, Irene; Dreyer, ZoAnn E.; Hudson, Melissa M.; Robison, Leslie L.; Yasui, Yutaka; Relling, Mary V.; Bhatia, Smita.

In: Journal of Clinical Oncology, Vol. 32, No. 7, 01.03.2014, p. 647-653.

Research output: Contribution to journalArticle

Wang, X, Liu, W, Sun, CL, Armenian, SH, Hakonarson, H, Hageman, L, Ding, Y, Landier, W, Blanco, JG, Chen, L, Quinõnes, A, Ferguson, D, Winick, N, Ginsberg, JP, Keller, F, Neglia, JP, Desai, S, Sklar, CA, Castellino, SM, Cherrick, I, Dreyer, ZE, Hudson, MM, Robison, LL, Yasui, Y, Relling, MV & Bhatia, S 2014, 'Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: A report from the children's oncology group', Journal of Clinical Oncology, vol. 32, no. 7, pp. 647-653. https://doi.org/10.1200/JCO.2013.50.3557
Wang, Xuexia ; Liu, Wei ; Sun, Can Lan ; Armenian, Saro H. ; Hakonarson, Hakon ; Hageman, Lindsey ; Ding, Yan ; Landier, Wendy ; Blanco, Javier G. ; Chen, Lu ; Quinõnes, Adolfo ; Ferguson, Daniel ; Winick, Naomi ; Ginsberg, Jill P. ; Keller, Frank ; Neglia, Joseph P. ; Desai, Sunil ; Sklar, Charles A. ; Castellino, Sharon M. ; Cherrick, Irene ; Dreyer, ZoAnn E. ; Hudson, Melissa M. ; Robison, Leslie L. ; Yasui, Yutaka ; Relling, Mary V. ; Bhatia, Smita. / Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy : A report from the children's oncology group. In: Journal of Clinical Oncology. 2014 ; Vol. 32, No. 7. pp. 647-653.
@article{fce81af0e4c944399c59fae5422333a6,
title = "Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: A report from the children's oncology group",
abstract = "Purpose: The strong dose-dependent association between anthracyclines and cardiomyopathy is further exacerbated by the co-occurrence of cardiovascular risk factors (diabetes and hypertension). The high morbidity associated with cardiomyopathy necessitates an understanding of the underlying pathogenesis so that targeted interventions can be developed. Patients and Methods: By using a two-stage design, we investigated host susceptibility to anthracycline-related cardiomyopathy by using the ITMAT/Broad CARe cardiovascular single nucleotide polymorphism (SNP) array to profile common SNPs in 2,100 genes considered relevant to de novo cardiovascular disease. Results: By using a matched case-control design (93 cases, 194 controls), we identified a common SNP, rs2232228, in the hyaluronan synthase 3 (HAS3) gene that exerts a modifying effect on anthracycline dose-dependent cardiomyopathy risk (P = 5.3 × 10-7). Among individuals with rs2232228 GG genotype, cardiomyopathy was infrequent and not dose related. However, in individuals exposed to high-dose (> 250 mg/m2) anthracyclines, the rs2232228 AA genotype conferred an 8.9-fold (95{\%} CI, 2.1- to 37.5-fold; P = .003) increased cardiomyopathy risk compared with the GG genotype. This gene-environment interaction was successfully replicated in an independent set of 76 patients with anthracycline-related cardiomyopathy. Relative HAS3 mRNA levels measured in healthy hearts tended to be lower among individuals with AA compared with GA genotypes (P = .09). Conclusion: Hyaluronan (HA) produced by HAS3 is a ubiquitous component of the extracellular matrix and plays an active role in tissue remodeling. In addition, HA is known to reduce reactive oxygen species (ROS)-induced cardiac injury. The high cardiomyopathy risk associated with AA genotype could be due to inadequate remodeling and/or inadequate protection of the heart from ROS-mediated injury on high anthracycline exposure.",
author = "Xuexia Wang and Wei Liu and Sun, {Can Lan} and Armenian, {Saro H.} and Hakon Hakonarson and Lindsey Hageman and Yan Ding and Wendy Landier and Blanco, {Javier G.} and Lu Chen and Adolfo Quin{\~o}nes and Daniel Ferguson and Naomi Winick and Ginsberg, {Jill P.} and Frank Keller and Neglia, {Joseph P.} and Sunil Desai and Sklar, {Charles A.} and Castellino, {Sharon M.} and Irene Cherrick and Dreyer, {ZoAnn E.} and Hudson, {Melissa M.} and Robison, {Leslie L.} and Yutaka Yasui and Relling, {Mary V.} and Smita Bhatia",
year = "2014",
month = "3",
day = "1",
doi = "10.1200/JCO.2013.50.3557",
language = "English (US)",
volume = "32",
pages = "647--653",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "7",

}

TY - JOUR

T1 - Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy

T2 - A report from the children's oncology group

AU - Wang, Xuexia

AU - Liu, Wei

AU - Sun, Can Lan

AU - Armenian, Saro H.

AU - Hakonarson, Hakon

AU - Hageman, Lindsey

AU - Ding, Yan

AU - Landier, Wendy

AU - Blanco, Javier G.

AU - Chen, Lu

AU - Quinõnes, Adolfo

AU - Ferguson, Daniel

AU - Winick, Naomi

AU - Ginsberg, Jill P.

AU - Keller, Frank

AU - Neglia, Joseph P.

AU - Desai, Sunil

AU - Sklar, Charles A.

AU - Castellino, Sharon M.

AU - Cherrick, Irene

AU - Dreyer, ZoAnn E.

AU - Hudson, Melissa M.

AU - Robison, Leslie L.

AU - Yasui, Yutaka

AU - Relling, Mary V.

AU - Bhatia, Smita

PY - 2014/3/1

Y1 - 2014/3/1

N2 - Purpose: The strong dose-dependent association between anthracyclines and cardiomyopathy is further exacerbated by the co-occurrence of cardiovascular risk factors (diabetes and hypertension). The high morbidity associated with cardiomyopathy necessitates an understanding of the underlying pathogenesis so that targeted interventions can be developed. Patients and Methods: By using a two-stage design, we investigated host susceptibility to anthracycline-related cardiomyopathy by using the ITMAT/Broad CARe cardiovascular single nucleotide polymorphism (SNP) array to profile common SNPs in 2,100 genes considered relevant to de novo cardiovascular disease. Results: By using a matched case-control design (93 cases, 194 controls), we identified a common SNP, rs2232228, in the hyaluronan synthase 3 (HAS3) gene that exerts a modifying effect on anthracycline dose-dependent cardiomyopathy risk (P = 5.3 × 10-7). Among individuals with rs2232228 GG genotype, cardiomyopathy was infrequent and not dose related. However, in individuals exposed to high-dose (> 250 mg/m2) anthracyclines, the rs2232228 AA genotype conferred an 8.9-fold (95% CI, 2.1- to 37.5-fold; P = .003) increased cardiomyopathy risk compared with the GG genotype. This gene-environment interaction was successfully replicated in an independent set of 76 patients with anthracycline-related cardiomyopathy. Relative HAS3 mRNA levels measured in healthy hearts tended to be lower among individuals with AA compared with GA genotypes (P = .09). Conclusion: Hyaluronan (HA) produced by HAS3 is a ubiquitous component of the extracellular matrix and plays an active role in tissue remodeling. In addition, HA is known to reduce reactive oxygen species (ROS)-induced cardiac injury. The high cardiomyopathy risk associated with AA genotype could be due to inadequate remodeling and/or inadequate protection of the heart from ROS-mediated injury on high anthracycline exposure.

AB - Purpose: The strong dose-dependent association between anthracyclines and cardiomyopathy is further exacerbated by the co-occurrence of cardiovascular risk factors (diabetes and hypertension). The high morbidity associated with cardiomyopathy necessitates an understanding of the underlying pathogenesis so that targeted interventions can be developed. Patients and Methods: By using a two-stage design, we investigated host susceptibility to anthracycline-related cardiomyopathy by using the ITMAT/Broad CARe cardiovascular single nucleotide polymorphism (SNP) array to profile common SNPs in 2,100 genes considered relevant to de novo cardiovascular disease. Results: By using a matched case-control design (93 cases, 194 controls), we identified a common SNP, rs2232228, in the hyaluronan synthase 3 (HAS3) gene that exerts a modifying effect on anthracycline dose-dependent cardiomyopathy risk (P = 5.3 × 10-7). Among individuals with rs2232228 GG genotype, cardiomyopathy was infrequent and not dose related. However, in individuals exposed to high-dose (> 250 mg/m2) anthracyclines, the rs2232228 AA genotype conferred an 8.9-fold (95% CI, 2.1- to 37.5-fold; P = .003) increased cardiomyopathy risk compared with the GG genotype. This gene-environment interaction was successfully replicated in an independent set of 76 patients with anthracycline-related cardiomyopathy. Relative HAS3 mRNA levels measured in healthy hearts tended to be lower among individuals with AA compared with GA genotypes (P = .09). Conclusion: Hyaluronan (HA) produced by HAS3 is a ubiquitous component of the extracellular matrix and plays an active role in tissue remodeling. In addition, HA is known to reduce reactive oxygen species (ROS)-induced cardiac injury. The high cardiomyopathy risk associated with AA genotype could be due to inadequate remodeling and/or inadequate protection of the heart from ROS-mediated injury on high anthracycline exposure.

UR - http://www.scopus.com/inward/record.url?scp=84899145885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899145885&partnerID=8YFLogxK

U2 - 10.1200/JCO.2013.50.3557

DO - 10.1200/JCO.2013.50.3557

M3 - Article

VL - 32

SP - 647

EP - 653

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 7

ER -